NAFLD and NASH: etiology, targets and emerging therapies

Drug Discov Today. 2024 Feb 1;29(3):103910. doi: 10.1016/j.drudis.2024.103910. Online ahead of print.ABSTRACTNon-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) pose a significant threat to human health and cause a tremendous socioeconomic burden. Currently, the molecular mechanisms of NAFLD and NASH remain incompletely understood, and no effective pharmacotherapies have been approved. In the past five years, significant advances have been achieved in our understanding of the pathomechanisms and potential pharmacotherapies of NAFLD and NASH. Research advances include the investigation of the effects of the fibroblast growth factor 21 (FGF21) analog pegozafermin and the thyroid hormone receptor-β (THRβ) agonist resmetriom on hepatic fat content, NASH resolution and/or fibrosis regression. Future directions of NAFLD and NASH research (including combination therapy, organoids and humanized mouse models) are also discussed in this state-of-the-art review.PMID:38301798 | DOI:10.1016/j.drudis.2024.103910
Source: Drug Discovery Today - Category: Drugs & Pharmacology Authors: Source Type: research